About 1% of the breast and ovarian Spanish families testing negative for BRCA1 and BRCA2 are carriers of RAD51D pathogenic variants

et al.RAD51D mutations have been recently identified in breast (BC) and ovarian cancer (OC) families. Although an etiological role in OC appears to be present, the association of RAD51D mutations and BC risk is more unclear. We aimed to determine the prevalence of germline RAD51D mutations in Spanish BC/OC families negative for BRCA1/BRCA2 mutations. We analyzed 842 index patients: 491 from BC/OC families, 171 BC families, 51 OC families and 129 patients without family history but with early-onset BC or OC or metachronous BC and OC. Mutation detection was performed with high-resolution melting, denaturing high-performance liquid chromatography or Sanger sequencing. Three mutations were found in four families with BC and OC cases (0.82%). Two were novel: c.1A>T (p.Met1?) and c.667+2_667+23del, leading to the exon 7 skipping and one previously described: c.674C>T (p.Arg232*). All were present in BC/OC families with only one OC. The c.667+2_667+23del cosegregated in the family with one early-onset BC and two bilateral BC cases. We also identified the c.629C>T (p.Ala210Val) variant, which was predicted in silico to be potentially pathogenic. About 1% of the BC and OC Spanish families negative for BRCA1/BRCA2 are carriers of RAD51D mutations. The presence of several BC mutation carriers, albeit in the context of familial OC, suggests an increased risk for BC, which should be taken into account in the follow-up and early detection measures. RAD51D testing should be considered in clinical setting for families with BC and OC, irrespective of the number of OC cases in the family.Grant sponsor: Miguel Servet Program, Spanish Carlos III Health Institute; Grant number: CP10/00617; Grant sponsor: Fondo de Investigación Sanitaria (FIS) Research; Grant number: PI 12/00539; Grant sponsor: Intrasalud; Grant number: PI12/00070; Grant sponsor: Xunta de Galicia; Grant number: 10PXIB 9101297PR; Grant sponsors: Mutua Madrileña Foundation (FMMA); Grant sponsor: Acción Cooperativa y Colaborativa Intramural-CIBER2012, SAF2010-20493; Grant sponsor: Cancer Prevention Program of the Regional Government of Castilla y León.Peer Reviewe